Bird H A, Leatham P A, Lowe J R, Downie W W, Fowler P D, Wright V
Eur J Clin Pharmacol. 1983;24(6):773-6. doi: 10.1007/BF00607086.
Different doses of phenylbutazone have been compared in a double blind study on 32 patients with rheumatoid arthritis in order to determine the minimum effective dose. Of 8 different dose levels studied (90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg and 450 mg/day) the most efficacious was found to be 300 mg/day. Doses below this did not produce full benefit; no further improvement occurs with higher doses. Although 7/32 patients developed adverse reactions there was no relationship between these and the plasma levels of either phenylbutazone or oxyphenbutazone. An attempt was made to distinguish 'responders' from 'non-responders'. We found no relationship between response and plasma levels of phenylbutazone or oxyphenbutazone.
为确定最小有效剂量，在一项针对32例类风湿性关节炎患者的双盲研究中比较了不同剂量的保泰松。在所研究的8种不同剂量水平（90毫克、150毫克、180毫克、240毫克、270毫克、300毫克、360毫克和450毫克/天）中，发现最有效的剂量为300毫克/天。低于此剂量不能产生充分疗效；更高剂量也不会带来进一步改善。虽然32例患者中有7例出现了不良反应，但这些反应与保泰松或羟基保泰松的血浆水平之间没有关系。曾试图区分“反应者”和“无反应者”。我们发现反应与保泰松或羟基保泰松的血浆水平之间没有关系。
